Argatroban

In the clinical anticoagulant treatment of acute ischemic stroke and thromboembolic diseases, traditional heparin drugs have the limitations of high bleeding risk and the need for frequent monitoring of coagulation indicators. As a small-molecule direct thrombin inhibitor, argatroban provides a more accurate anticoagulation option for such patients. It can selectively bind to the active site of thrombin, block fibrin production and platelet aggregation, and is not affected by the level of antithrombin Ⅲ. It has an inhibitory effect on both free and bound thrombin. Clinically, it is mainly used to improve neurological function in patients with acute ischemic stroke, and can also be used to improve ischemic symptoms such as ulcers and rest pain caused by chronic arterial occlusive disease, as well as anticoagulant treatment for patients with heparin-induced thrombocytopenia. The applicable population covers patients with thrombosis-related diseases in multiple departments such as neurology, cardiovascular department, and peripheral vascular department.

The global argatroban market size was approximately USD 420 million in 2023, and is expected to continue to expand at a compound annual growth rate of 6.8% from 2024 to 2030. The growth drivers mainly come from the rising prevalence of stroke and the improvement of the diagnosis and treatment rate of peripheral vascular diseases. In the domestic market, the sales of argatroban at the terminal of public medical institutions exceeded RMB 1.2 billion in 2022, and the competitive landscape is dominated by generic drugs. At present, generic preparations of more than 10 enterprises have been approved for marketing. In 2022, this variety was included in the seventh batch of national centralized drug procurement, with an average price reduction of more than 70% for the selected products, which further promoted the improvement of clinical accessibility and also drove the continuous growth of demand for upstream API.

The original research enterprise of argatroban is Japan's Mitsubishi Tanabe Pharma, and the original brand name is Novastan. Its U.S. compound patent expired in 2014, and the core compound patent in China expired in 2009. The main dosage form approved by the original research is injection, with specifications including 20ml:10mg and 2ml:10mg. Among them, the 20ml:10mg specification has been included in the *Catalogue of Reference Preparations of Chemical Drugs* of China, and is also included in the FDA Reference Preparation Catalogue. In terms of domestic API registration, at present, argatroban APIs of more than 20 enterprises have completed registration and been activated in CDE, including a number of domestic enterprises and a small number of imported manufacturers. A number of domestic enterprises have obtained approval for the marketing of argatroban injection and argatroban for injection preparations. (Data as of June 2025, please refer to the official CDE website for the latest information)

CATO provides a full set of argatroban impurity reference standards, which fully meet the needs of multiple scenarios such as generic drug consistency evaluation and API quality research. Most products are in stock regularly, and orders placed before 16:00 can be shipped on the same day. All reference standards meet the requirements of multiple regulations such as Chinese Pharmacopoeia and FDA, and can effectively help improve the efficiency of quality control in R&D and production links.